- Home
- ALDX vs ESPR Comparison
ALDX vs ESPR Comparison
Compare ALDX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- ESPR
- Stock Information
- Founded
- ALDX 2004
- ESPR 2008
- Country
- ALDX United States
- ESPR United States
- Employees
- ALDX N/A
- ESPR N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- ESPR Health Care
- Exchange
- ALDX Nasdaq
- ESPR Nasdaq
- Market Cap
- ALDX 304.9M
- ESPR 305.0M
- IPO Year
- ALDX 2014
- ESPR 2013
- Fundamental
- Price
- ALDX $6.91
- ESPR $1.50
- Analyst Decision
- ALDX Strong Buy
- ESPR Buy
- Analyst Count
- ALDX 2
- ESPR 7
- Target Price
- ALDX $10.00
- ESPR $6.36
- AVG Volume (30 Days)
- ALDX 607.7K
- ESPR 3.9M
- Earning Date
- ALDX 05-01-2025
- ESPR 03-04-2025
- Dividend Yield
- ALDX N/A
- ESPR N/A
- EPS Growth
- ALDX N/A
- ESPR N/A
- EPS
- ALDX N/A
- ESPR N/A
- Revenue
- ALDX N/A
- ESPR $332,314,000.00
- Revenue This Year
- ALDX N/A
- ESPR $5.51
- Revenue Next Year
- ALDX N/A
- ESPR $1.42
- P/E Ratio
- ALDX N/A
- ESPR N/A
- Revenue Growth
- ALDX N/A
- ESPR 185.66
- 52 Week Low
- ALDX $2.71
- ESPR $1.47
- 52 Week High
- ALDX $7.20
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ALDX 61.80
- ESPR 34.95
- Support Level
- ALDX $6.79
- ESPR $1.47
- Resistance Level
- ALDX $7.20
- ESPR $1.61
- Average True Range (ATR)
- ALDX 0.56
- ESPR 0.13
- MACD
- ALDX 0.03
- ESPR -0.01
- Stochastic Oscillator
- ALDX 88.02
- ESPR 7.69
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.